v3.26.1
Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment - Footnotes (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 28, 2026
Jun. 29, 2025
Jun. 28, 2026
Jun. 29, 2025
Segment Reporting [Line Items]        
Income from continuing operations before provision/(benefit) for taxes on income [1] $ (653) $ 3,044 $ 2,517 $ 5,828
Certain asset impairments [2] 4,325 93 4,325 317
Certain legal matters, net [3] 842 422 1,033 564
Net gain from the sale of investment in ViiV [4] 1,870 0 1,870 0
Restructuring charges and certain acquisition-related costs 591   717  
Restructuring charges       670
ViiV [Member]        
Segment Reporting [Line Items]        
Dividend income (98) (73) (180) (111)
Biopharma [Member]        
Segment Reporting [Line Items]        
Income from continuing operations before provision/(benefit) for taxes on income 6,887 6,891 13,725 13,960
Biopharma [Member] | ViiV [Member]        
Segment Reporting [Line Items]        
Dividend income (98) (73) (180) (111)
Other Business Activities [Member]        
Segment Reporting [Line Items]        
Income from continuing operations before provision/(benefit) for taxes on income [1],[5] $ (1,708) (1,762) $ (3,376) (3,146)
Other Business Activities [Member] | Reclassification Other [Member]        
Segment Reporting [Line Items]        
Income from continuing operations before provision/(benefit) for taxes on income   $ 38   $ 74
[1] Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss). Effective in the third quarter of 2025, certain expenses for corporate affairs, which were previously reported in the operating results of corporate enabling functions, are reported in the operating results of our Biopharma reportable segment. In connection with this reporting change, we reclassified Selling, informational and administrative expenses of approximately $38 million in the second quarter of 2025 and $74 million in the first six months of 2025 from Other business activities to Biopharma to conform to the current period presentation.
[2] The amounts for the second quarter and first six months of 2026 represent intangible asset impairment charges associated with our Biopharma segment, composed of: (i) $3.8 billion in impairments of IPR&D assets, associated with a Phase 3 study for sigvotatug vedotin for the second line treatment of metastatic non-squamous NSCLC, reflecting unfavorable clinical trial results, and (ii) $525 million for Oxbryta (voxelotor) developed technology rights, after engaging with the FDA in July 2026 to discuss their assessment of data and analyses, and it was determined there was no viable pathway to return Oxbryta to the market in the U.S. The amount for the first six months of 2025 primarily included an intangible asset impairment charge associated with our Biopharma segment of $210 million for a Phase 2 indefinite-lived out-licensed asset that was discontinued by our out-licensing partner.
[3] The amounts for the second quarter and first six months of 2026 and 2025 primarily include certain product liability and other legal expenses.
[4] See Note 2C.
[5] Other business activities include revenues and costs associated with PC1 and our former operating segment, Pfizer Ignite, as well as costs that we do not allocate to our operating segments, per above.